Maciocia, Paul M
Wawrzyniecka, Patrycja A
Philip, Brian
Ricciardelli, Ida
Akarca, Ayse U
Onuoha, Shimobi C
Legut, Mateusz
Cole, David K
Sewell, Andrew K http://orcid.org/0000-0003-3194-3135
Gritti, Giuseppe
Somja, Joan
Piris, Miguel A
Peggs, Karl S
Linch, David C
Marafioti, Teresa
Pule, Martin A http://orcid.org/0000-0002-8347-9867
Article History
Received: 20 July 2016
Accepted: 18 October 2017
First Online: 13 November 2017
Competing interests
: P.M.M. and M.A. Pule have patent rights for the targeting of TRBC for diagnosis and treatment of T cell malignancies (patent application, World Intellectual Property Organization, WO 2015132598 A1). P.M.M., B.P., S.C.O., K.S.P., D.C.L. and M.A. Pule are shareholders in Autolus, which has licensed anti-TRBC1 technology. S.C.O. and M.A. Pule are also employees of Autolus.